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BACKGROUND/PURPOSE: Drug-resistant tuberculosis (TB) is an important issue for public health. 
This study was conducted to evaluate the prevalence of drug resistance to Mycobacterium tuberculosis com-
plex at Changhua Christian Hospital in central Taiwan.
METHODS: We retrospectively reviewed 1,961 non-duplicate isolates of M. tuberculosis complex from 
2003 to 2007. The following data were collected: demographic characteristics, previous anti-TB therapy 
and drug susceptibility testing. Antimicrobial drug susceptibility testing was performed using the 
BACTEC MGIT 960 System from January 2003 to February 2005. Starting in March 2005, the agar pro-
portion method was used for antimicrobial drug susceptibility testing.
RESULTS: A total of the 1,961 patients were analyzed. The majority (66.5%) of cases were ≥ 65 years of 
age. A total of 151 patients had undergone previous anti-TB treatment. Individual drug resistance was as 
follows: 229 isolates (11.7%) were resistant to isoniazid, 55 (2.8%) to rifampin, 49 (2.5%) to ethambutol, 
and 218 (11.1%) to streptomycin. The overall resistance to any drug was 19.1%, while 39 isolates (2.0%) 
were resistant at least to isoniazid and rifampin (multidrug-resistant). A significant decreasing trend in 
resistance rates to the four first-line anti-TB drugs, and any other drug, was observed during the 5-year 
period. Drug resistance was associated with a history of previous anti-TB treatment (p = 0.017).
CONCLUSION: The study found a significant decrease in drug resistance from 2003 to 2007. The multi-
drug resistance also decreased, although this was not statistically significant. This decreasing resistance 
rate may be due to the effect of the direct observed treatment, short-course strategy which was enhanced 
in Taiwan after 2006.
KEYWORDS: drug resistance, HIV, Mycobacterium tuberculosis complex
286
C.C. Yu, et al
Introduction
Tuberculosis (TB) is a major cause of illness and death 
worldwide, especially in Asia and Africa. The World Health 
Organization (WHO) estimates that 9.2 million new cases 
of TB occurred in 2006 (139 per 100,000 population). Asia 
(South-East Asia and Western Pacific regions) accounts 
for 55% of global cases, and Africa accounts for 31%. 
Among the 9.2 million new cases of TB in 2006, 4.1 million 
were new smear-positive cases (44%) and 0.7 million human 
immunodeficiency virus (HIV)-positive cases (8%). The 
global incidence peaked around 2003, but has now stabi-
lized. However, because of population growth in Asia, Africa 
and Europe, the number of new cases was still increasing 
between 2005 and 2006—from 9.1 million to 9.2 million.1 
In addition, multidrug resistant (MDR)-TB, which is re-
sistant to isoniazid (INH) and rifampin (RIF), emerged 
worldwide. The WHO estimated the number of incident 
MDR-TB cases was 489,139 in 2006. Three countries, China, 
India, and Russia, accounted approximately 50% of the 
global burden of MDR-TB.2
A notification system for TB cases was established in 
Taiwan in July 1997; if there were any suspected TB cases 
reported to the public health administration, the hospital 
would not receive any reimbursement from the National 
Health Insurance. Because of this, more TB cases have been 
identified.3 In 2006, the Centers for Disease Control (CDC) 
of Taiwan reported 15,378 newly diagnosed TB cases. 
An incidence of 67.4 cases per 100,000 population and a 
mortality rate of 3.6 deaths per 100,000 population were 
reported.4 The incidence was higher in aborigines and in 
people living in mountainous counties or regions.5
INH was introduced for TB treatment in 1952 and RIF 
in 1978. In Taiwan, drug-resistant pulmonary TB has been 
reported since 1962.6 Wu et al reported primary drug re-
sistance in Taiwan from October 1970 to September 1972 
as follows: INH 22.6%, ethambutol (EMB) 0.2%, strepto-
mycin 15.4% and any drug 30.8%.6 Primary resistance rates 
to RIF have increased in the recent decade as a result of 
RIF-containing mass chemotherapy.5 In addition, both 
MDR-TB and extensively-drug-resistant TB have emerged 
as a challenge. Since drug resistance is a critical indicator 
of TB control, the laboratory-based Taiwan Surveillance 
of drug resistance was established in 2003.7 Continuing 
the published study discussing the drug resistance rate in 
central Taiwan from July 2001 through June 2002,8 this 
study aimed to further analyze drug resistance trends from 
2003 to 2007.
Methods
Patients
Changhua Christian Hospital is a 1,613-bed teaching hos-
pital in central Taiwan, providing both acute and chronic 
care services. The study analyzed the records of all patients 
with positive Mycobacterium tuberculosis complex (MTBC) 
cultures between January 2003 and December 2007. When 
multiple isolates were obtained from a patient, only the 
first isolate was analyzed. Information was collected on 
demographic characteristics of age and sex, HIV tests,
history of TB and any previous therapy.
Laboratory procedures
All drug susceptibility tests were performed in the myco-
bacteriology laboratory of the Changhua Christian 
Hospital. Prior to the end of 2004, the digested and de-
contaminated specimens were inoculated into a Myco-
bacteria Growth Indicator Tube (MGIT) and placed into 
the BACTEC MGIT 960 system (Becton Dickinson, Sparks, 
MD, USA) for culture. Since the end of 2004, in addition 
to the MGIT 960 system, the specimens were cultured 
on Löwenstein-Jensen media. After the identification of 
MTBC, a BACTEC MGIT 960 SIRE kit was used for anti-
microbial susceptibility testing (AST) prior to March 1, 
2005. Critical concentrations of INH (0.1 μg/mL), RIF 
(1.0 μg/mL), EMB (5.0 μg/mL), and streptomycin (1.0 μg/
mL) were tested. After March 1, 2005, this method was re-
placed by the agar proportion method. Middlebrook 
7H10 agar was used for AST, containing the standard sen-
sitive strain, H37Rv, for quality control. The media com-
prised were 0.2 μg/mL INH, 1.0 μg/mL RIF, 5.0 μg/mL 
EMB and 2.0 μg/mL streptomycin. Organisms were con-
sidered resistant to a given drug if any growth ≥ 1% of the 
drug free control was observed.
Primary resistance was defined as the presence of drug 
resistance in new cases, or in patients who had received anti-
TB treatment for < 1 month. Drug resistance among previ-
ously treated cases was defined as resistance in patients who 
had already received anti-TB therapy for ≥ 1 month, or 
were retreated. Combined resistance was defined as any 
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resistance regardless of previous treatment. MDR-TB was 
resistant to INH and RIF.
Statistical analysis
Statistical analyses were performed using SPSS version 
15.0 (SPSS Inc., Chicago, IL, USA). Differences in drug re-
sistance between different age groups, sexes, or previous 
anti-TB treatment were analyzed using the χ2 test or 
Fisher’s exact test. Trends in drug resistance were evalu-
ated by logistic regression analysis. A p value of < 0.05 was 
considered statistically significant.
Results
During the 5-year study period, 92,808 specimens submit-
ted for mycobacterial cultures from inpatient and outpa-
tient services and yielded 4,945 isolates of MTBC (positive 
rate, 5.3%). A total of 1,961 first isolates with AST were 
collected. Of the 1,961 isolates, 1,712 (87.3%) were from 
respiratory secretions (sputum and bronchial washing), 
101 (5.2%) from pleural effusions, 31 (1.6%) from urine, 
18 (0.9%) from gastric juices, 16 (0.8%) from cerebrospinal 
fluid, 13 (0.7%) from pericardial effusions, 13 (0.7%) from 
ascites, and the rest 57 (2.9%) from other specimens in-
cluding synovial fluid, abscess, bone, blood, and tissue. 
There were 1,353 men and 608 women with a mean age 
of 67.5 years. Two-third of cases were ≥ 65 years of age. 
A total of 151 patients had a previous history of anti-TB 
therapy for ≥ 1 month.
Of these first isolates, 229 (11.7%) were resistant to 
INH, 55 (2.8%) to RIF, 49 (2.5%) to EMB and 218 (11.1%) 
to streptomycin. Overall, 19.1% of isolates were resistant to 
one or more drugs. Thirty-nine isolates (2.0%) were resistant 
to at least INH and RIF. The trend of drug resistance dur-
ing 2003–2007 is shown in Table 1. A significant decrease 
in the resistance rates to the first-line drugs, or any drug, 
was noted (p < 0.05). The decreasing trend was significant, 
especially after 2006 (p = 0.009 and p = 0.034 for any drug 
resistance; Table 2). A comparison of drug resistance be-
tween patients with and without previous anti-TB therapy 
is shown in Table 3. Higher resistance rates to INH, RIF, 
EMB, streptomycin, and higher MDR was seen in those 
patients that had been previously treated (p < 0.05).
The drug resistance was reviewed by sex and age 
(Table 4). The overall drug resistant rate was higher in 
those aged 45–64 years (25.2%), followed by those aged 
25–44 years (19.6%), those aged < 25 years (18.8%), and 
those aged ≥ 65 years (17.0%). MDR-TB was highest among 
the group aged 25–44 years (4.5%) compared with the 
groups aged 45–64 years (3.5%) and ≥ 65 years (1.2%). The 
drug resistant rate was similar in male (19.3%) and female 
(18.8%) patients (p = 0.778). However, a significant differ-
ence was noted (p = 0.003) between the different age groups.
Of the 1,961 patients, an HIV screening test was availa-
ble for 222 (11.3%) patients. Of these, seven (3.2%) patients 
had HIV infection as confirmed by Western blot. Sixty-five 
patients had been tested for HIV antibody before diagnosis 
of TB, and four were HIV-positive. The remaining 157 
Table 1. Resistance to first-line anti-tuberculosis agents, 2001–2002 and 2003–2007
 No. of resistant isolates (%)
Drugs 2001–2002, from 
2003
 
2004
 
2005 2006 2007 Total
 pb
 Liu CE et al [8]a
 (n = 513) 
(n = 397)
 
(n = 448)
 
(n = 403) (n = 396) (n = 317) (n = 1,961)
INH 86 (16.8) 63 (15.9) 47 (10.5) 52 (12.9) 36 (9.1) 31 (9.8) 229 (11.7) 0.010
RIF  25 (4.9) 16 (4.0) 13 (2.9) 15 (3.7) 7 (1.8) 4 (1.3) 55 (2.8) 0.010
EMB 21 (4.1) 11 (2.8) 16 (3.6) 13 (3.2) 8 (2.0) 1 (0.3) 49 (2.5) 0.016
SM 63 (12.3) 51 (12.8) 60 (13.4) 39 (9.7) 40 (10.1) 28 (8.8) 218 (11.1) 0.026
Any drug 115 (22.4) 93 (23.4) 92 (20.5) 77 (19.1) 61 (15.4) 52 (16.4) 375 (19.1) 0.002
MDR-TB 20 (3.9) 11 (2.8) 8 (1.8) 11 (2.7) 6 (1.5) 3 (0.9) 39 (2.0) 0.104
aThe drug susceptibility test was performed by the BACTEC MGIT 960 system; bχ2 test for trend from 2003 to 2007. INH = Isoniazid; RIF = 
rifampin; EMB = ethambutol; SM = streptomycin; MDR-TB = multidrug resistant tuberculosis.
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patients were tested for HIV antibody after TB diagnosis, 
and three (1.9%) were HIV-seropositive.
Discussion
The WHO reported that the global incidence of TB peaked 
around 2003 and appeared to stabilize, or began to de-
cline. However, the number of new cases increased between 
2005 and 2006.1 The estimated TB burden varied in 
different countries. In 2006, the estimated incidence in 
Taiwan, calculated from the WHO equation, was 87 per 
100,000 per year; and the estimated prevalence was 113 
per 100,000 per year.4 The results were similar to those of 
Republic of Korea, but higher than those in Hong Kong 
(incidence of 62 per 100,000 per year; prevalence of 64 per 
100,000 per year) and Singapore (incidence of 26 per 
100,000 per year; prevalence of 25 per 100,000 per year). 
In Taiwan, the number of new TB cases declined from 
16,784 cases in 2004 to 15,378 in 2006. In this study 
(from 2003 to 2007), which combines the data of a previ-
ous study by Liu8 from 2001 to 2002, the number of cases 
also decreased gradually—from 513 to 317 (Table 1). 
There may be many factors influencing the incidence of 
TB, e.g. direct observed treatment, short course (DOTS) 
strategy, HIV prevalence and others. DOTS may have a 
great impact on decreasing TB transmission. However, 
DOTS can be augmented by a more integrated approach or 
other developments, e.g. HIV control, rapid and accurate 
diagnosis, new drugs or new vaccines.9
The Global Project on Anti-Tuberculosis Drug Resis-
tance Surveillance was initiated in 1994.10,11 In new cases 
of TB, the median prevalence of resistance to any drug 
during 2002–2007 was 11.1%, and to MDR was 1.6%.10 
The prevalence of MDR among new cases ranged from 0% 
in eight countries to 22.3% in Baku and Azerbaijan. In 
previously treated cases, the median prevalence of resis-
tance to any drug was 25.1% and to MDR was 11.7%. This 
study revealed that the drug resistance rate at this hospi-
tal in central Taiwan was close to the global median rate. 
Compared with the resistance rate in Hong Kong (11.1% 
any drug and 0.9% MDR in new cases) and Singapore 
(6.5% any drug and 0.2% MDR in new cases), this study 
showed higher drug resistance rates, whereas the resis-
tance rates were lower than that in the Republic of Korea.
The combined resistance reported in Taiwan from 1982 
to 2004 was: INH = 13.9–35.9%, RIF = 4.9–18.2%, EMB = 4.1–
15.7%, streptomycin = 8.3–28.6% and MDR = 3.9–17.3%.7 
Table 3. Drug resistance among patients with or without 
previous anti-tuberculous therapy
 No. of resistant isolates (%)
 Without previous With previous Drugs
 TB therapy TB therapy 
p
 (n = 1,810) (n = 151)
INH 202 (11.2) 27 (17.9) 0.013
RIF 36 (2.0) 19 (12.6) 0.000
EMB 39 (2.2) 10 (6.6) 0.003
SM 192 (10.6) 26 (17.2) 0.013
Any drug 335 (18.5) 40 (26.5) 0.017
MDR-TB 23 (1.3) 16 (10.6) 0.000
INH = Isoniazid; RIF = rifampin; EMB = ethambutol; SM = streptomycin; 
MDR-TB = multidrug resistant tuberculosis.
Table 4. Drug resistance, by sex and age
  Any drug  Multidrug
 Total resistancea p resistance
  n (%)  n (%)
Sex
 Male 1,353 261 (19.3) 0.778 31 (2.3)
 Female 608 114 (18.8)  8 (1.3)
Age group
 < 25 64 12 (18.8) 0.003 0 (0)
 25–44 179 35 (19.6)  8 (4.5)
 45–64 433 109 (25.2)  15 (3.5)
 ≥ 65 1,285 219 (17.0)  16 (1.2)
aRefers to “at least one drug”.
Table 2. Logistic regression analysis of drug resistance from 
2003 to 2007
  Resistance Multiple analysis
Year Total 
n (%) OR (95% CI) p
2003 397 93 (23.4) 1.000
2004 448 92 (20.5) 0.851 (0.613–1.180) 0.333
2005 403 77 (19.1) 0.793 (0.563–1.116) 0.183
2006 396 61 (15.4) 0.618 (0.431–0.886) 0.009
2007 317 52 (16.4) 0.664 (0.454–0.969) 0.034
OR = Odds ratio; CI = confidence interval.
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From recent reports,12–15 the combined resistance to any 
drug was 23.4% in northern Taiwan, 52.4% in southern 
Taiwan and 28.6% in eastern Taiwan. The combined 
resistance to any drug in this study was much lower 
than that in northern, southern and eastern Taiwan. In 
addition, the overall drug resistance of individual first-
line drugs in this study was lower than that in previous 
studies,12,13,15 except for the overall drug resistance to 
streptomycin, which was lower in eastern Taiwan. This 
finding was the same for MDR-TB. Overall, drug resis-
tance was lower at this hospital than in other regions. This 
may be due to a smaller number of TB cases in central 
Taiwan and certain patients with MDR-TB being trans-
ferred to referral hospitals.
In this study, the drug resistance trends for first-line 
drugs or any drug significantly decreased, (also noted in 
northern and southern Taiwan).12,13 Compared with the 
data from 2001–2002 in the report by Liu,8 the resistance 
rate during 2003–2007 was lower (although resistance to 
any drug or streptomycin was higher in 2003, but de-
creased thereafter). It may, therefore, be concluded that 
drug resistance was decreasing in western Taiwan. Start-
ing in 2006, DOTS was strengthened in Taiwan and may 
have contributed to this study result, which found a sig-
nificant decrease in 2006 and 2007. This result was not 
due to the different AST, since the agar proportion method 
was used after March 2005. Although DOTS may be one 
reason for the decreasing resistance rate, many other factors 
such as patient characteristics, case number, non-referral 
center and local TB control program may have influenced 
drug resistance in this hospital. To observe the full effect 
of DOTS, long-term follow-up is needed.
As expected, the resistance rate observed in this study 
was higher in previously treated patients (p < 0.05), as re-
ported previously.14,16,17 The resistance rate to any drug 
was similar in men and women, but men were more likely 
to have MDR-TB than women, which is different to re-
sults in previous studies.17–19 We found that age was a sig-
nificant factor in the development of drug resistance. 
Younger patients showed higher resistance rates than 
those ≥ 65 years. Resistance to any drug was highest in 
those aged 45–64 years, and those aged 25–44 years had 
the highest rate of MDR. WHO mentioned that MDR-TB 
was likely to be associated with male sex and a younger 
age group (25–44 years).2 Our data show similar results. 
There may be many factors contributing to these age and 
sex differences, e.g. the year in which they received effec-
tive anti-TB drug20 or patient compliance.
The association between TB and HIV/acquired immu-
nodeficiency syndrome (AIDS) has frequently been dis-
cussed. The prevalence of HIV infection in new TB cases 
varies between regions and countries: from 1% in the 
Western Pacific region to 38% in the African region. Nine 
percent (7–12%) of all new TB cases in adults aged 15–49 
years are attributable to HIV infection.21 Screening for 
HIV is recommended for patients with TB, and HIV testing 
of TB patients has increased from around 20,000 patients 
in 2002 to almost 700,000 patients in 2006.22 In 1996 in 
Taiwan, Chiang et al reported that only 1/378 patients 
with active pulmonary TB had HIV, but HIV infection was 
still not significant at that time.23 However, cases of HIV/
AIDS have increased recently in Taiwan. In 2004, drug 
injection led to a rise in HIV infection in Taiwan; thus the 
prevalence of HIV in 2004 was 18.09 per 100,000 popula-
tion. The number of HIV cases had risen to 15,651 by 
2007.3 Clinicians are alert to TB in Taiwan, but the detec-
tion of HIV infection may be delayed or neglected. The CDC 
in Taiwan reported that 0.7% of new TB patients in 2006 
were HIV positive.4 A recent study from a medical center 
in northern Taiwan reported that the prevalence of HIV 
infection among TB patients was 5.6%.24
As previously mentioned, 222/1,961 TB patients were 
tested for HIV. Of these, 3.2% were HIV positive, while the 
HIV prevalence rate among the TB patients reported by 
the CDC was 0.7%. There were 1,739 (1,961 minus 222) 
untested patients, which may have resulted in higher rates 
of HIV diagnosis. The increase in suspected cases may 
have been 55 (1,739 multiplied by 3.2%) or seven (1,739 
multiplied by 0.7%). Thus HIV screening is very important 
in TB cases.
This study had some limitations. First, the method 
used for AST was different before March 2005. As a result, 
the critical concentrations of INH and streptomycin were 
not the same. Second, as this was a retrospective study, 
some data may be incomplete.
In conclusion, this study shows a significant decrease 
in drug resistant TB from 2003 to 2007. As expected, re-
sistance to anti-TB drugs was associated with previous epi-
sodes of anti-TB treatment. Although DOTS may have been 
effective in controlling TB, MDR-TB remains a challenge. 
290
C.C. Yu, et al
More policies should be established to strengthen MDR-TB 
control. Also, because of the TB/HIV co-infection, more 
attention should be paid to HIV screening for TB patients.
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